Augmedics closed $82.5 million in series D financing to support the growth of Xvision, the medtech company said June 27.
The funding round comes as the company marked its 4,000th U.S. patient treated with the augmented reality spine system, according to a news release. The money will grow Xvision's reach in the U.S. and support future platform advancements.
Funding was led by Dallas-based CPMG and adds Evidity Health Capital as a syndicate partner. Kent McGaughy, of CPMG, and Paul Enever of Evidity, will join Augmedics' board of directors.